Please do not leave this page until complete. This can take a few moments.
Marlborough medical device maker Boston Scientific has acquired a privately-held California company in a deal that could be worth up to $300 million. The company hopes to eventually market a device to more effectively treat atrial defibrillation. Joe Fitzgerald, president of Rhythm Management at Boston Scientific, answered questions about the acquisition and future plans for the device.
This acquisition is another step in the company’s continued investment in the electrophysiology (EP) space and demonstrates our commitment to broadening the depth and breadth of our solutions in order to address the clinical needs of our global customers. Upon commercialization of the Apama radiofrequency (RF) balloon catheter system, Boston Scientific will have an expanded EP portfolio, which will contain the industry’s only true high-density, high-resolution mapping system – RHYTHMIA HDx Mapping System – and an expanded toolkit of RF point-by-point and single-shot balloon ablation technologies.
The Apama RF balloon – a single-shot, multi-electrode technology – is designed to combine the primary benefits of both RF point-by-point and balloon-based ablation approaches, notably the ability to deliver differentiated levels of energy and shortened procedure times. The technology incorporates built-in digital cameras with LED lights and sensing electrodes on the balloon which allow for real-time visualization and assessment of catheter electrode contact. This is intended to provide physicians with higher confidence of effective energy delivery and the ability to customize the amount of energy delivered around the circumference of the balloon, while further reducing procedure times when compared to existing balloon technologies.
The transaction consists of $175 million in cash up-front and a maximum of $125 million in contingent payments over the period of 2018-2020 based on achievements of clinical and regulatory milestones.
Our existing EP portfolio includes a RF point-by-point ablation solution – one of the two standard technologies used for pulmonary vein isolation (PVI) ablation. This acquisition enables us to expand our offerings into the second category: single-shot PVI ablation, a method associated with shortened procedure times and operator ease of use.
The CE Mark is anticipated in late 2018 with European commercialization to begin following regulatory approval.
Boston Scientific welcomes all Apama team members to the company.
Stay connected! Every business day, WBJ Daily Report will be delivered to your inbox by noon. It provides a daily update of the area’s most important business news.
Sign upWorcester Business Journal provides the top coverage of news, trends, data, politics and personalities of the Central Mass business community. Get the news and information you need from the award-winning writers at WBJ. Don’t miss out - subscribe today.
SubscribeWorcester Business Journal presents a special commemorative edition celebrating the 300th anniversary of the city of Worcester. This landmark publication covers the city and region’s rich history of growth and innovation.
See Digital EditionStay connected! Every business day, WBJ Daily Report will be delivered to your inbox by noon. It provides a daily update of the area’s most important business news.
Worcester Business Journal provides the top coverage of news, trends, data, politics and personalities of the Central Mass business community. Get the news and information you need from the award-winning writers at WBJ. Don’t miss out - subscribe today.
Worcester Business Journal presents a special commemorative edition celebrating the 300th anniversary of the city of Worcester. This landmark publication covers the city and region’s rich history of growth and innovation.
In order to use this feature, we need some information from you. You can also login or register for a free account.
By clicking submit you are agreeing to our cookie usage and Privacy Policy
Already have an account? Login
Already have an account? Login
Want to create an account? Register
In order to use this feature, we need some information from you. You can also login or register for a free account.
By clicking submit you are agreeing to our cookie usage and Privacy Policy
Already have an account? Login
Already have an account? Login
Want to create an account? Register
This website uses cookies to ensure you get the best experience on our website. Our privacy policy
To ensure the best experience on our website, articles cannot be read without allowing cookies. Please allow cookies to continue reading. Our privacy policy
0 Comments